Treatment of epilepsy in patients with Alzheimer’s disease

References

• Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2014;10(2):e47–e92.
   Web of Science ®Google Scholar
• Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 Census. Neurology. 2013;80(19):1778–1783.
   PubMed Web of Science ®Google Scholar
• Liu AK, Chang RC, Pearce RK, et al. Nucleus basalis of meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129(4):527–540.
   PubMed Web of Science ®Google Scholar
• Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. J Comp Neurol. 2013;521(18):4124–4144.
   PubMed Web of Science ®Google Scholar
• Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470–472.
   PubMed Web of Science ®Google Scholar
• Hauser WA, Morris ML, Heston LL, et al. Seizures and myoclonus in patients with Alzheimer’s disease. Neurology. 1986;36(9):1226–1230.
   PubMed Web of Science ®Google Scholar
• Sjogren H, Sourander P. Histopathological studies in Alzheimer’s disease. In: Jacob H, editor. IV international congress of neuropathology. Stuttgart: Georg Thieme Verlag; 1961 Sep 4-8. MQnchen, Vol III Neuropathology.
   Google Scholar
• Friedman D, Honig LS, Scarmeas N. Seizures and epilepsy in Alzheimer’s disease. CNS Neurosci Ther. 2012;18(4):285–294.
   PubMed Web of Science ®Google Scholar
• Giorgi FS, Baldacci F, Dini E, et al. Epilepsy occurrence in patients with Alzheimer’s disease: clinical experience in a tertiary dementia center. Neurol Sci. 2016;37(4):645–647.
   PubMed Web of Science ®Google Scholar
• Cabrejo L, Guyant-Maréchal L, Laquerrière A, et al. Phenotype associated with APP duplication in five families. Brain. 2006;129(Pt 11):2966–2976.
   PubMed Web of Science ®Google Scholar
• Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(Pt 4):1143–1154.
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol. 2009;66(8):992–997.
   PubMedGoogle Scholar
• Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70(9):1158–1166.
   PubMed Web of Science ®Google Scholar
• Braidy N, Muñoz P, Palacios AG, et al. Recent rodent models for Alzheimer’s disease: clinical implications and basic research. J Neural Transm (Vienna). 2012;119(2):173–195.
   PubMed Web of Science ®Google Scholar
• Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007;55:697–711.
   PubMed Web of Science ®Google Scholar
• Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443(7113):768–773.
   PubMed Web of Science ®Google Scholar
• Cretin B, Sellal F, Philippi N, et al. Epileptic prodromal Alzheimer’s disease, a retrospective study of 13 new cases: expanding the spectrum of Alzheimer’s disease to an epileptic variant? J Alzheimers Dis. 2016;52:1125–1133.
   PubMed Web of Science ®Google Scholar
• Forsgren L, Beghi E, Oun A, et al. The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol. 2005;12:245–253.
   PubMed Web of Science ®Google Scholar
• Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy – a review. Epilepsy Res. 2009;85:31–45.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000;22;355(9213):1441–1446.
   Web of Science ®Google Scholar
• Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019–1030.
   PubMed Web of Science ®Google Scholar
• Blechman MB, Gelb AM. Aging and gastrointestinal physiology. Clin Geriatr Med. 1999;15(3);429–438.
   PubMed Web of Science ®Google Scholar
• Christensen H, Baker M, Tucker GT, et al. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci. 2006;95(12):2778–2787.
   PubMed Web of Science ®Google Scholar
• Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging. 2000;17(6):441–452.
   PubMed Web of Science ®Google Scholar
• Ahn JE, Cloyd JC, Brundage RC, et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology. 2008;71:38–43.
   PubMed Web of Science ®Google Scholar
• Werhahn KJ. Epilepsy in the elderly. Dtsch Arztebl Int. 2009;106:135–142.
   PubMed Web of Science ®Google Scholar
• Faught E. Monotherapy in adults and elderly persons. Neurology. 2007;69(24 Suppl 3):S3- S9.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Kelly K, Mohanraj R, et al. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav. 2006;8:434–437.
   PubMed Web of Science ®Google Scholar
• Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 2006;68(Suppl 1):S49–63.
   PubMed Web of Science ®Google Scholar
• Leppik IE, Walczak TS, Birnbaum AK. Challenges of epilepsy in elderly people. Lancet. 2012;29(9848):1128–1130.
   Google Scholar
• Pugh MJ, Van Cott AC, Cramer JA, et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology. 2008;70(22 Pt 2):2171–2178.
   PubMed Web of Science ®Google Scholar
• Bruun E, Virta LJ, Kälviäinen R, et al. Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy: a Finnish retrospective study. Seizure. 2015;31:27–32.
   PubMed Web of Science ®Google Scholar
• Perucca E, Alexandre V, Tomson T. Old versus new antiepileptic drugs: the SANAD study. Lancet. 2007;370(9584):313.
   PubMed Web of Science ®Google Scholar
• Johnell K, Fastbom J. Antiepileptic drug use in community-dwelling and institutionalized elderly: a nationwide study of over 1,300,000 older people. Eur J Clin Pharmacol. 2011;67(10):1069–1075.
   PubMed Web of Science ®Google Scholar
• Galimberti CA, Tartara E, Dispenza S, et al. Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: a reappraisal 12 years after a first survey. Epilepsy Res. 2016;119:41–48.
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Pugh MJ. Pharmacoepidemiology in community-dwelling elderly taking antiepileptic drugs. Int Rev Neurobiol. 2007;81:153–163.
   PubMed Web of Science ®Google Scholar
• Ferlazzo E, Sueri C, Gasparini S, et al. Challenges in the pharmacological management of epilepsy and its causes in the elderly. Pharmacol Res. 2016;106:21–26.
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868–1873.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999;37(1):81–87.
   PubMed Web of Science ®Google Scholar
• Korabathina K, Benbadis SR. Levetiracetam is as effective as carbamazepine in newly diagnosed epilepsy. Expert Rev Neurother. 2007;7(6):599–601.
   PubMedGoogle Scholar
• Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56(3):450–459.
   PubMed Web of Science ®Google Scholar
• Romigi A, Femia EA, Fattore C, et al. Zonisamide in the management of epilepsy in the elderly. Clin Interv Aging. 2015;10:931–937.
   PubMed Web of Science ®Google Scholar
• Sommer BR, Fenn HH. Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging. 2010;5:89–99.
   PubMed Web of Science ®Google Scholar
• Stefan H, Hubbertz L, Peglau I, et al. Epilepsy outcomes in elderly treated with topiramate. Acta Neurol Scand. 2008;118(3):164–174.
   PubMed Web of Science ®Google Scholar
• Saetre E, Perucca E, Isojärvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48(7):1292–1302.
   PubMed Web of Science ®Google Scholar
• Ramsay RE, Uthman B, Pryor FM, et al. Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia. 2008;49(7):1180–1185.
   PubMed Web of Science ®Google Scholar
• Pandis D, Scarmeas N. Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr. 2012;12(5):184–187.
   PubMed Web of Science ®Google Scholar
• Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20(11):791–803.
   PubMed Web of Science ®Google Scholar
• Rao SC, Dove G, Cascino GD, et al. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009;14(1):118–120.
   PubMed Web of Science ®Google Scholar
• Tsiouris JA, Patti PJ, Tipu O, et al. Adverse effects of phenytoin given for late-onset seizures in adults with Down syndrome. Neurology. 2002;59(5):779–780.
   PubMed Web of Science ®Google Scholar
• Tsiouris JA, Patti PJ. Drug treatment of depression associated with dementia or presented as ‘pseudodementia’ in older adults with Down syndrome. J Intellect Disabil Res. 1997;10(4):312–322.
   Web of Science ®Google Scholar
• Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16(9):564–574.
   PubMed Web of Science ®Google Scholar
• Mark RJ, Ashford JW, Goodman Y, et al. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging. 1995;16(2):187–198.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev. 2002;54(12):1567–1577.
   PubMed Web of Science ®Google Scholar
• for Alzheimer’s Disease Cooperative Study, Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011;77(13):1263–1271.
   PubMed Web of Science ®Google Scholar
• for Alzheimer’s Disease Cooperative Study Group, Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68(8):853–861.
   PubMed Web of Science ®Google Scholar
• Karas BJ, Wilder BJ, Hammond EJ, et al. Valproate tremors. Neurology. 1982;32:428–432.
   PubMed Web of Science ®Google Scholar
• Easterford K, Clough P, Kellett M, et al. Reversible Parkinsonism with normal β -CIT–SPECT in patients exposed to sodium valproate. Neurology. 2004;62:1435–1437.
   PubMed Web of Science ®Google Scholar
• Belcastro V, Costa C, Galletti F, et al. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol. 2007;14(10):1176–1178.
   PubMed Web of Science ®Google Scholar
• Lippa CF, Rosso A, Hepler M, et al. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Demen. 2010;25(2):149–154.
   PubMed Web of Science ®Google Scholar
• Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav. 2010;17(4):461–466.
   PubMed Web of Science ®Google Scholar
• Turski WA, Cavalheiro EA, Schwarz M, et al. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathologicalstudy. Behav Brain Res. 1983;9(3):315–359.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Bortz JJ, Blum DE, et al. A pilot study of donepezil for memory problems in epilepsy. Epilepsy Behav. 2001;2(4):330–334.
   PubMed Web of Science ®Google Scholar
• Hamberger MJ, Palmese CA, Scarmeas N, et al. A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy. Epilepsia. 2007;48(7):1283–1291.
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012;69(3):368–372.
   PubMedGoogle Scholar
• Peltz G, Pacific DM, Noviasky JA, et al. Seizures associated with memantine use. Am J Health Syst Pharm. 2005;62(4):420–421.
   PubMed Web of Science ®Google Scholar
• Savić A, Mimica N. Two cases of loss of consciousness after long-term memantine treatment. J Am Med Dir Assoc. 2013;14(5):375–376.
   PubMed Web of Science ®Google Scholar
• Mares P, Mikulecká A. Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav. 2009;14(1):32–39.
   PubMed Web of Science ®Google Scholar
• Serdyuk SE, Gmiro VE, Veselkina OS. Combined blockade of NMDA and AMPA receptors prevents acute kainate seizures and chronic kainate lethality in rats. Bull Exp Biol Med. 2014;157(1):15–17.
   PubMed Web of Science ®Google Scholar
• Dhir A, Chopra K. Memantine delayed N-methyl-D-aspartate-induced convulsions in neonatal rats. Fundam Clin Pharmacol. 2015;29(1):72–78.
   PubMed Web of Science ®Google Scholar
• Zaitsev AV, Kim KK, Vasilev DS, et al. N-methyl-D-aspartate receptor channel blockers prevent pentylenetetrazole-induced convulsions and morphological changes in rat brain neurons. J Neurosci Res. 2015;93(3):454–465.
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110.
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F, Trimble MR. Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk. Expert Rev Neurother. 2004;4(6):953–964.
   PubMedGoogle Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–481.
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs. 2009;23(2):121–137.
   PubMed Web of Science ®Google Scholar
• Trimble MR, Dodson WE. Epilepsy and quality of life. New York: Raven Press; 1994.
   Google Scholar
• Aldenkamp AP. Antiepileptic drug treatment and epileptic seizures: effects on cognitive function. In: Trimble MR, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press; 2002.
   Google Scholar
• MacLeod CM, Dekabian AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentration. Science. 1978;202:1102–1104.
   PubMed Web of Science ®Google Scholar
• Gallassi R, Morreale A, Di Sarro R, et al. Cognitive effects of antiepileptic drug discontinuation. Epilepsia. 1992;33(Suppl 6):S41- S4.
   PubMed Web of Science ®Google Scholar
• Thompson P, Huppert FA, Trimble M. Phenytoin and cognitive function: effects on normal volunteers and implications for epilepsy. Br J Clin Psychol. 1981;20(3):155–162.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology. 1991;41(10):1537–1540.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia. 1993;34(1):153–157.
   PubMed Web of Science ®Google Scholar
• Thompson PJ, Trimble MR. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol. 1981;12(6):819–824.
   PubMed Web of Science ®Google Scholar
• Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning: comparison with carbamazepine. the Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol. 1996;53(10):1008–1016.
   PubMedGoogle Scholar
• Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single blind randomized comparative study. Epilepsia. 1994;35(2):381–390.
   PubMed Web of Science ®Google Scholar
• Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006;67(3):400–406.
   PubMed Web of Science ®Google Scholar
• Bootsma HP, Aldenkamp AP, Diepman L, et al. The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia. 2006;47(Suppl 2):24–27.
   PubMed Web of Science ®Google Scholar
• Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011;76(2):131–137.
   PubMed Web of Science ®Google Scholar
• Aikiä M, Kälviäinen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. 1992;11(3):199–203.
   PubMed Web of Science ®Google Scholar
• Salinsky MC, Spencer DC, Oken BS, et al. Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers. Epilepsy Behav. 2004;5(6):894–902.
   PubMed Web of Science ®Google Scholar
• Placidi F, Marciani MG, Diomedi M, et al. Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. Acta Neurol Scand. 2000;102(2):81–86.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001;56(9):1177–1182.
   PubMed Web of Science ®Google Scholar
• Leach JP, Girvan J, Paul A, et al. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry. 1997;62(4):372–376.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia. 1999;40(9):1279–1285.
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhang Q, Tian L, et al. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav. 2008;12(2):305–310.
   PubMed Web of Science ®Google Scholar
• Koo DL, Hwang KJ, Kim D, et al. Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients. Eur Neurol. 2013;70(1–2):88–94.
   PubMed Web of Science ®Google Scholar
• Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A. 2012;109(42):E2895- E903.
   PubMed Web of Science ®Google Scholar
• Shi JQ, Wang BR, Tian YY, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19(11):871–881.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Zheng CY, Zou MM, et al. Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice. Neurobiol Aging. 2014;35(12):2713–2725.
   PubMed Web of Science ®Google Scholar